Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gossamer Bio Inc GOSS

Healthcare Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor... see more

Recent & Breaking News (NDAQ:GOSS)

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Business Wire 1 day ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Business Wire March 12, 2024

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Business Wire March 5, 2024

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 8, 2024

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Business Wire December 13, 2023

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 5, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Business Wire December 5, 2023

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Business Wire November 29, 2023

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Business Wire November 9, 2023

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Business Wire October 3, 2023

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Gossamer Bio, Inc.; Urges Gossamer Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Accesswire October 2, 2023

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Business Wire August 8, 2023

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Business Wire July 24, 2023

Gossamer Bio Announces $212 Million Private Placement Financing

Business Wire July 20, 2023

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Business Wire May 18, 2023

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Business Wire May 9, 2023

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Business Wire March 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

PR Newswire February 6, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

Newsfile February 2, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

Newsfile December 30, 2022